A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

Part of paid clinical trials in Glendale, California.

Sponsor
AstraZeneca
Study ID
NCT07404137
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to investigate the concentrations of zibotentan and dapagliflozin in blood when given with and without food in healthy participants.

Key Dates

Start date
Feb 16, 2026
Status verified
Apr 2026
Primary completion
Apr 2, 2026
Completion
Apr 2, 2026

Study Design

Enrollment
26 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment AB
    Participants will receive single dose of Zibotentan/Dapagliflozin FDC after an overnight fast of at least 10 hours (Treatment A). After a washout period, participants will receive another single dose of Zibotentan/Dapagliflozin FDC 30 minutes after having a high-fat, high-calorie standardized meal (Treatment B).
  • Experimental: Treatment BA
    Participants will receive single dose of Zibotentan/Dapagliflozin FDC 30 minutes after having a high-fat high-calorie standardized meal (Treatment B). After a washout period, participants will receive another single dose of Zibotentan/Dapagliflozin FDC after an overnight fast of at least 10 hours (Treatment A).

Primary Outcome Measure

Area under concentration-time curve from time 0 to infinity (AUCinf) [ Time Frame: At predefined intervals from Day 1 to Day 4 for both treatment periods ]

Locations (1)

FacilityCityStateZIPSite coordinators
Research SiteGlendaleCalifornia91206-

Find similar trials in Glendale, CA

By research site
Research Site· Glendale, CA

Related Studies